Analyses of tumor tissues in mice treated with the different immunotherapies produced results that may be best explained when considering the combination treatment as a sum of all the benefits induced by each therapeutic approach, namely, the combined increase in CD4+ T cells induced by p-Tvax and the increase in CD8+ T cells induced by OX40 agonists. Here, TNFRSF4 is linked to neoplasm.